RxDoctor Payments Data

Nina Ni, MD

Ophthalmology · Santa Rosa, CANPI 1780959734

Payments from drug & device makers

$943in general payments, 2019–2025

Across 38 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$463
  • Dompe US, Inc.$98
  • Bausch & Lomb Americas Inc.$56
  • Amgen$46
  • Biotissue Holdings Inc.$45
  • Tarsus Pharmaceuticals, Inc.$38
  • plus $197 from 8 others

What the payments were for

  • Food & beverage$943100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$943 in reported general payments places this provider in the 40th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$469,559
Medicare patients
943
Services billed
2,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine48$66,337
MieboPerfluorohexyloctane/Pf32$23,694
Prednisolone Acetate452$23,264
LumiganBimatoprost15$9,166
CequaCyclosporine14$8,866
Cyclosporine20$7,863
Brimonidine Tartrate94$7,007
RhopressaNetarsudil Mesylate13$6,100
SimbrinzaBrinzolamide/Brimonidine Tart18$4,198
Fluorometholone43$3,674
Loteprednol Etabonate16$3,309
Latanoprost177$2,984
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat117$2,226
ValacyclovirValacyclovir Hcl22$1,974
Dexamethasone Sodium Phosphate45$1,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$38$75,50363 claims
Bausch & Lomb Americas Inc.Miebo$56$23,69432 claims
Sun Pharmaceutical Industries Inc.Cequa$16$8,86614 claims
Aerie Pharmaceuticals, Inc.Rhopressa$16$6,10013 claims
AlconSimbrinza$463$4,19818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →